Jerusalem, Israel, December 16 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, announce the publication of its latest article in the prestigious Journal of Investigative Dermatology (2018, vol 138:2635-2643), discussing the discovery of Vidac’s anti-cancer drug VDA-1102 and its pre-clinical characterization. This peer-reviewed article establishes that VDA-1102’s mechanism of action is blocking the ‘glycolysis metabolic program’ in cancer cells forcing them to undergo programmed cell death. This is supported by data from multiple laboratory systems as well as in vivo efficacy, and lack of local skin reactions, in a mouse model of UVB-induced skin cancer. VDA-1102 is now in phase 2b clinical development for treating an early form of skin cancer, known as actinic keratosis (AK) which can develop to invasive squamous cell carcinoma of the skin.
Link to the article: " A Hexokinase 2 Modulator for Field-Directed Treatment of Experimental Actinic Keratoses. "
About VDA-1102 ointment
VDA-1102 is a novel, potent selective allosteric modulator of HK2 detaching it from the mitochondria of cancer cells as well as certain immune cells. Exposure to VDA-1102 triggers apoptosis in cancer cells by detaching hexokinase 2 (HK2) from the mitochondria. The drug also leads to glycolysis inhibition, reduction of immunosuppression in the tumor microenvironment, and to stimulation of an anti-tumor immune response. The selective profile of VDA-1102, which targets malignant cells without affecting the surrounding healthy tissue, offers a broad therapeutic window. VDA-1102 is being developed as a topical ointment for treatment of actinic keratosis (AK) and other non-melanoma skin cancers. VDA-1102 ointment has successfully completed a Phase 2a proof-of-concept study in subjects with AK, demonstrating efficacy, safety, and excellent tolerability, and is now in Phase 2b trial. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors.
About Vidac Pharma
Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac is using its proprietary HEXAGON™ bioinformatics tool to identify patients with cancers that have high HK2 levels, across a variety of tumor types. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.
For more information regarding Vidac Pharma, please visit www.vidacpharma.com.
Contact: Shelly Majar +972-2-5952090